rs121434569
|
|
|
0.040 |
GeneticVariation |
BEFREE |
The EGFR resistance mutation T790M should be monitored at cancer progression.
|
31445213 |
2019 |
rs121434569
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Liquid biopsies (LB) are used routinely in clinical practice in two situations for late stage non-small-cell lung cancer (NSCLC) patients, (i) at the initial diagnosis when looking for activating mutations in EGFR in the absence of analyzable tissue DNA and, (ii) during tumor progression on a tyrosine kinase inhibitor treatment to look for the resistance mutation T790M in EGFR.
|
29069959 |
2017 |
rs121434569
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Finally, in the prospective series, SiRe detected 8.7% (4/46) of EGFR mutations at baseline and 42.9% (9/21) of EGFR p.T790M in patients at tumour progression.
|
28170370 |
2017 |
rs121434569
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Detection of T790M with plasma DNA was correlated with EGFR mutation type, exon 19 deletions and tumor progression.
|
26577492 |
2016 |
rs961150162
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The DDR2 E655K mutation can play a role in cancer progression by reducing the growth-inhibitory effect of collagen.
|
26826182 |
2016 |
rs1057519847
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Haploinsufficiency of Nkx2-1 enhanced Kras(G12D)-mediated tumor progression, but reduced EGFR(L858R)-mediated progression.
|
23143308 |
2012 |
rs1057519848
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Haploinsufficiency of Nkx2-1 enhanced Kras(G12D)-mediated tumor progression, but reduced EGFR(L858R)-mediated progression.
|
23143308 |
2012 |
rs121434568
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Haploinsufficiency of Nkx2-1 enhanced Kras(G12D)-mediated tumor progression, but reduced EGFR(L858R)-mediated progression.
|
23143308 |
2012 |
rs2227983
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The common EGFR-R521K genotype (G/G) was significantly associated with increased skin toxicity (P = 0.024) and showed a trend toward reduced risk of tumor progression (hazard ratio, 0.55; 95% confidence interval, 0.27-1.08; P = 0.08), whereas no correlation of the EGFR-R521K genotype with OS could be observed (P = 0.20).
|
20028750 |
2010 |